Glucotrack completes merger with Lōkahi Therapeutics, ceding control
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro softer after ECB stands pat on rates
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
July 16, 2026 4:57 PM EDTTransaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform
RUTHERFORD, N.J. and LA JOLLA, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with Lkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets.
The transaction is structured such that Lkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging... More
